Keywords: Sanofi-Aventis, Genzyme, Alemtuzumab, Lemtrada, Campath, Contingent value right, M&A
Sanofi-Aventis confirms it is considering CVR-based deal regarding takeover of Genzyme
Article | 10 January 2011
Following intense rumor and speculation over the weekend, late Sunday, French drug major Sanofi-Aventis (Euronext: SAN) confirmed that talks with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
